Paid Clinical Trials Cambridge

Discover 2,936 paid clinical trials in Cambridge, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,936

Therapeutic Evaluative Conditioning to Reduce Adolescents' Self-injurious Thoughts and Behaviors During and After Psychiatric Inpatient HospitalizationTherapeutic Evaluative Conditioning to Reduce Adolescents' Self-injurious Thoughts and Behaviors During and After Psychiatric Inpatient Hospitalization

Recruiting

Sponsor:

Franciscan Hospital For Children, INC.

Location:

Brighton MA

Code:

NCT05796531

Conditions

Self-Injurious Behavior

Suicidal Ideation

Suicide Attempts

Eligibility Criteria

Sex: All

Age: 12 - 19

Healthy Volunteers: Not accepted

Interventions

Therapeutic Evaluative Conditioning

Neutral comparison condition

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting

PHASE1

PHASE2

Sponsor:

Tango Therapeutics, Inc.

Location:

Boston MA, New York NY, Fairfax VA, Detroit MIshow 8 more

Code:

NCT05732831

Conditions

Locally Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TNG462

Pembrolizumab

Understanding Chronic Lymphocytic LeukemiaUnderstanding Chronic Lymphocytic Leukemia

Recruiting

Sponsor:

Dana-Farber Cancer Institute

Location:

Boston MA

Code:

NCT04028531

Conditions

Chronic Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Dabrafenib + Trametinib + PDR001 In Colorectal CancerDabrafenib + Trametinib + PDR001 In Colorectal Cancer

Recruiting

PHASE2

Sponsor:

Massachusetts General Hospital

Location:

Boston MA

Code:

NCT03668431

Conditions

Metastatic Colorectal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dabrafenib

Trametinib

PDR001

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery LesionsMagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Recruiting

Sponsor:

Concept Medical Inc.

Location:

Boston MA, New Haven CT, Bronx NY, New York City NYshow 21 more

Code:

NCT05908331

Conditions

In-Stent Restenosis

Cardiovascular Diseases

Coronary Artery Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Sirolimus Drug Coated Balloon

Plan balloon Angioplasty (POBA)

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCINBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting

PHASE2

PHASE3

Sponsor:

Inhibrx Biosciences, Inc

Location:

Boston MA, Detroit MI, Louisville KY, Saint Louis MOshow 10 more

Code:

NCT06295731

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INBRX-106

Pembrolizumab

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) AmyloidosisA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

Recruiting

PHASE2

Sponsor:

Janssen Research & Development, LLC

Location:

Boston MA, New Haven CT, New York NY, Torontoshow 14 more

Code:

NCT05250973

Conditions

Amyloidosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daratumumab

Cyclophosphamide

Bortezomib

Dexamethasone

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Boston MA, Plymouth MA, East Providence RI, Providence RIshow 125 more

Code:

NCT06268873

Conditions

Chronic Kidney Disease and Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Baxdrostat/dapagliflozin

Dapagliflozin in combination with placebo

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerTesting the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Recruiting

PHASE1

Sponsor:

National Cancer Institute (NCI)

Location:

Boston MA, Columbus OH, Nashville TN

Code:

NCT05422794

Conditions

Anatomic Stage III Breast Cancer AJCC v8

Anatomic Stage IV Breast Cancer AJCC v8

Locally Advanced Triple-Negative Breast Carcinoma

Metastatic Triple-Negative Breast Carcinoma

Unresectable Triple-Negative Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BET Bromodomain Inhibitor ZEN-3694

Biopsy

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

Recruiting

Sponsor:

Carelon Research

Location:

Boston MA, New York NY, Philadelphia PA, Washington DCshow 20 more

Code:

NCT05268094

Conditions

Congenital Heart Disease in Children

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Interventions

Ductal Arterial Stent

Systemic-to-Pulmonary Artery Shunt